May 4, 2011 . Executive Summary. Regeneron's VEGF Trap-Eye is caught in the crosshairs in

May 12, 2011 . The Regeneron drug VEGF Trap-Eye, now awaiting U.S. approval, uses the

theflyonthewall.com: Regeneron VEGF Trap-Eye to be challenged by data, says

Jun 17, 2011 . 1. VEGF TRAP-EYE. (aflibercept ophthalmic solution). OPHTHALMOLOGIC

Apr 8, 2011 . Regeneron Pharmaceuticals (NASDAQ:REGN) said Friday its VEGF Trap-Eye

Feb 25, 2011 . Regeneron Pharmaceuticals, Inc.announced that the company submitted a

Apr 8, 2011 . Bayer and partner Regeneron Pharmaceuticals have initiated the first of two

Regeneron's VEGF Trap Could Struggle in New AMD Landscape. Download Full

Nov 22, 2010 . Bayer HealthCare and Regeneron Pharmaceuticals say that two Phase III studies

Apr 27, 2011 . Regulatory applications for marketing approval in the US planned in second-half

Feb 23, 2011 . Regeneron Pharmaceuticals (Nasdaq: REGN) has submitted a Biologics License

May 13, 2011 . Regeneron Pharmaceuticals' VEGF Trap-Eye, which is undergoing FDA review

Jun 17, 2011 . Regeneron submitted a BLA for VEGF Trap-Eye for the treatment of wet age-

Jun 20, 2011 . FDA Advisory Panel recommends approval of Eylea.

Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the

Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap

Nov 23, 2010 . Regeneron has developed a chimeric (i.e., fusion) protein, which it refers to as

Jun 2, 2011 . Last week, the FDA announced that its Advisory Committee will meet on June 17,

Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) ( CBOE: REGN );

Jun 15, 2011 . Regeneron filed for European regulatory approval earlier this month. VEGF Trap-

FDA Staff Say Regeneron's VEGF Trap-Eye as Effective as Lucentis For Wet

Apr 18, 2011 . Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug

May 13, 2011 . From BioPortfolio: Regeneron Pharmaceuticals' VEGF Trap-Eye, which is

Regeneron and Bayer HealthCare are studying an investigational new

Apr 11, 2011 . Regeneron and Bayer HealthCare are collaborating on the global development

Apr 8, 2011 . VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational . A second

Feb 9, 2011 . TARRYTOWN, N.Y., Regeneron Pharmaceuticals, Inc. (Nasdaq REGN) today

Feb 13, 2012 . Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) ( CBOE: REGN );

Jun 29, 2011 . Bayer HealthCare and Regeneron are collaborating on the global development

Jun 20, 2011 . However, the entire US rights pertaining to VEGF trap-eye lie with Regeneron.

Regeneron submitted a Biologics License Application for marketing approval in

Jun 9, 2011 . Bayer HealthCare and Regeneron are collaborating on the global development

Feb 1, 2012 . Regeneron Pharmaceuticals Inc (REGN, Tarrytown, New York) has announced a

Apr 8, 2011 . Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that

Regeneron and Genentech's VEGF trap dispute settles. and continues. Patent

Apr 28, 2011 . Regeneron Pharmaceuticals and Bayer HealthCare have released positive top-

Regeneron has two products in development based on aflibercept, a VEGF . -

Mar 13, 2011 . Fierce Biotech reports that Sanofi and Regeneron's drug aflibercept (VEGF trap)

Apr 27, 2011 . 300px Human eye cross sectional view grayscale Regeneron announces

Jan 22, 2011 . Bayer HealthCare and Regeneron Pharmaceuticals say that two Phase III studies

Apr 18, 2011 . "We are very pleased that the FDA has chosen to grant priority review to VEGF

Jun 7, 2011 . Regeneron and Bayer HealthCare are collaborating on the global development

Apr 27, 2011 . ZALTRAP (aflibercept), also known as VEGF Trap, is an angiogenesis inhibitor.

Jun 7, 2011 . From Yahoo! Finance: Regeneron Pharmaceuticals announced that Bayer

Feb 9, 2011 . TARRYTOWN, N.Y., Feb. 9, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals,

Apr 27, 2011 . In GALILEO, the primary endpoint at week 24 was achieved: 60.2 percent of

May 3, 2011 . Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.

Apr 8, 2011 . Bayer and partner Regeneron Pharmaceuticals have initiated the first of two

Feb 22, 2011 . Regeneron's submission includes a request for Priority Review, which, . The

Feb 11, 2011 . Register for a webcast discussing data from VEGF Trap-Eye clinical studies.

Sitemap